Biolase (BIOL) PT Lowered to $2.75 at Ascendiant Capital
Tweet Send to a Friend
Ascendiant Capital analyst Edward Woo lowered the price target on Biolase (NASDAQ: BIOL) to $2.75 (from $3.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
